under-perform
reason report
hamlet quixot price upgrad mp pt
bottom line under-perform xbi year date
nearli sinc initi see core element
invest thesi reflect share price current level balanc
long-term clinic execut risk see note commerci viabil
upcom competitor data challeng see rgnx
pipelin attract potenti cash flow zolgensma see
peak world-wide zolgensma sale peak net royalti
 launch assumpt due zolgensma data manipul see
link lower pt parallel upgrad
rate share market perform base balanc
near-term risk/reward ahead upcom competitor wet data
septemb pipelin updat find difficult
compellingli argu investor deploy fresh capit either long
short basi present
upgrad market perform despit long-term headwind
believ current valuat balanc challeng
rgnx partnership strategi uncertain ip posit see
early-stag gene therapi pipelin attract anticip
royalti stream zolgensma competit risk
wet well-appreci investor continu
reserv long-term outlook compani intellectu
properti platform finit lifetim self-limit
royalti stream expos compani litig risk core
patent approach expiri expect rate new partnership
continu decreas also continu cautiou pipelin
view commerci viabil gene therapi requir
subretin surgeri wet limit best rgnx strategi
develop genet encod antibodi intrins riskier
develop gene therapi monogen loss-of-funct diseas
near-term risk/reward zolgensma balanc
risk balanc promis royalti stream zolgensma
see peak world-wide zolgensma sale peak net royalti
net royalti collect cours avxs/nv
partnership data manipul issu rais question regard
eu approv time launch dynam face risdiplam competit
entri modestli delay eu approv trim ou launch veloc
see concern around zolgensma bake share
price given fda public express displeasur partner
nv see fda statement suggest near-term risk/reward
skew upsid nv execut us launch
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep dilut
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
expect come wet data
upcom month immedi catalyst competitor
advm data patient phase optic trial
first efficaci readout compet wet gene therapi
success clinic develop believ would
meaning headwind due safer conveni
commerci appeal physician practic intravitr
administr see note convers investor
substanti risk price share event make
difficult us advoc initi new short posit share
current share price
chang model due disclosur data manipul
zolgensma market applic european japanes regul
push back time zolgensma approv quarter sma
market model flatten revenu ramp approv dont
believ data manipul impact zolgensma chanc approv
ex-u geographi continu model po believ
degre scrutini applic increas see link
could set nv back foot reimburs negoti ou ex-
us sale decreas
chang reduc pt
rate share market perform see headlin risk nvs/avx preclin
data manipul scandal broadli appreci investor remain optimist
zolgensma blockbust see current valuat adequ account robust
royalti stream zolgensma partner asset well compani wholli
own pipelin see crowd competit landscap challeng clinic practic
wet unclear commerci potenti
mucopolysaccharidos type ii mp mp ii clinic meaning data
homozyg famili hypercholesterolemia hofh yet disclos though see
robust clinic scientif rational program cautious optimist
futur data would justifi valu ascrib asset addit compani strong
cash posit potenti non-dilut capit ip licens posit limit balanc
sheet risk due mix risk/reward profil share across program near-
mid-term catalyst consid collect find difficult compellingli argu investor
deploy fresh capit either long short basi present
price target base dcf methodolog forecast risk-
adjust sale risk-adjust royalti
key partner program explicitli model expens result cash flow
assum discount rate consist clinic stage pre-revenu compani
coverag univers termin growth rate addit includ rgnx net cash
balanc valuat
risk view outlook valuat inc includ major chang
price reimburs coverag gene therapi agent unexpect safeti efficaci
signal clinic develop chang regulatori environ forecast subject
unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share aav-bas therapi develop partner
convers sale royalti forecast includ estim impact certain competit
agent agent fail enter market poorer-than-expect clinic profil
otherwis fail garner share expect could repres materi upsid
estim element compani busi model depend monet
core ip asset chang intellectu properti law enforc compani ip
portfolio could materi impact compani prospect futur cash flow
total cost revenu
research develop
gener administr
sale market
loss incom oper
interest incom licens
total incom expens
loss incom tax
compani report svb leerink equiti research estim
bs mm
cash equival
properti equip net
accru expens current liabil
defer rent net current portion
accumul comprehens loss incom
total liabil stockhold equiti
compani report svb leerink equiti research estim
chang
oper
net amort premium accret discount market debt secur
invest
financ
proce exercis stock option
compani report svb leerink equiti research estim
brand
type event
event trial detail
expect
submiss ind form batten
svb leerink llc equiti research compani file
